Cure My Disease

Don't miss your cure!

 Log in / Sign up

Old chemo drug gets new look for tough head and neck cancers

NCT ID NCT02369458

Completed Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested the chemotherapy drug mitomycin C in 48 patients with incurable head and neck cancer that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. Researchers hope to find a new option for patients with very limited choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Mitomycin C (a chemotherapy drug)
What this could lead to
If it works, this could offer a new treatment option for patients with head and neck cancer that has not responded to other therapies.
What could go wrong
This is a small, early-phase trial with only 48 participants. The drug may not shrink tumors or improve survival, and it can cause serious side effects like bone marrow suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK SQUAMOUS CELL CARCINOMA, HEAD AND NECK

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.